Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine Amine Congener SCHEMBL25227375 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| Xanthine Amine Congener SCHEMBL15124872 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL7038268 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL10420682 | 0.92 | ADORA2A (0.91) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL9159693 | 0.87 | ADORA2A (0.77) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| Xanthine Amine Congener SCHEMBL1755129 | 0.86 | ADORA2A (0.76) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL7220958 | 0.86 | ADORA2B (1.00) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL9164820 | 0.85 | ADORA2B (0.80) | ADORA2AADORA2BADORA3KDM4EALDH1A1 | |
| SCHEMBL7235224 | 0.85 | ADORA2B (1.00) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL14564549 | 0.84 | ADORA2A (0.75) | ADORA2AADORA2BADORA3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-20190209594-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML) | UNIVERSITE PAUL SABATIER TOULOUSE III (FR) | 2019-07-11 | — | — | US | claimed |
| EP-1846578-A2 | METHODS OF IDENTIFYING GENES WHICH MODULATE MYELINATION | Elan Pharmaceuticals Inc. (US) | 2007-10-24 | — | — | EP | claimed |
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | YASUDA MASAHIRO | 2007-03-08 | — | — | US | claimed |
| WO-2006086761-A2 | METHODS OF IDENTIFYING GENES WHICH MODULATE MYELINATION | ELAN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-20060183147-A1 | Methods of identifying genes which modulate myelination | ELAN PHARMACEUTICALS, INC. | 2006-08-17 | — | — | US | claimed |
| WO-2005079250-A2 | PURINES ARE SELF-RENEWAL SIGNALS FOR NEURAL STEM CELLS, AND PURINE RECEPTOR ANTAGONISTS PROMOTE NEURONAL AND GLIAL DIFFERENTIATION THEREFROM | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050181503-A1 | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-18 | — | — | US | claimed |
| EP-1510222-A2 | Medicinal compositions promoting bowel movement | Eisai Co. Ltd. (JP) | 2005-03-02 | — | — | EP | claimed |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-09-11 | — | — | US | claimed |
| EP-1283056-A1 | MEDICINAL COMPOSITIONS PROMOTING BOWEL MOVEMENT | Eisai Co., Ltd. (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020165197-A1 | Administering adenosine receptor ligand | CAN-FITE BIOPHARMA LTD. (IL) | 2002-11-07 | — | — | US | claimed |
| US-20020115635-A1 | Modulation of GSK-3beta activity and its different uses | CAN-FITE TECHNOLOGIES LTD. (IL) | 2002-08-22 | — | — | US | claimed |
| US-5424297-A | Adenosine dextran conjugates | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1995-06-13 | — | — | US | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-5298508-A | Compounds as ligands for cardiovascular disorders or stimulant of immunology | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-03-29 | — | — | US | disclosed |
| WO-1990012797-A1 | SULFER-CONTAINING XANTHINE DERIVATIVES AS ADENOSIN ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054876-A1 | Pharmaceutical composition promoting defecation | ADORA2B, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 1/4885ADORA3 4/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2A 1801/4885ADORA2B 2902/4885ADORA3 3648/4885 |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | ADORA2A 414/4885ADORA2B 826/4885ADORA3 473/4885 |
| US-20040259865-A1 | Pyrimidone compounds and pharmaceutical compositions containing the same | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA3 3/4885 |
| US-20030171383-A1 | Medicinal compositions promoting bowel movement | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.